The HPV test has similar sensitivity but more overdiagnosis than the Pap test - A randomised health services study on cervical cancer screening in Finland

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 2141-2147

  Malila, Nea ^a,b   Leinonen, Maarit ^a   Kotaniemi Talonen, Laura ^c   Laurila, Pekka ^d   Tarkkanen, Jussi ^d   Hakama, Matti ^a,b  

^a FINNISH CANCER REGISTRY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c PIRKANMAA HOSPITAL DISTRICT   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

cervical cancer; public health; randomisation; screening; sensitivity

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FINLAND; FOLLOW UP; HEALTH SERVICE; HUMAN; HUMAN PAPILLOMAVIRUS TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84874105574     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27850     Document Type: Article

References (34)

1. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
2. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
3. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross-sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56-61.
4. IARC. Handbooks of cancer prevention cervix cancer screening. Lyon: IARC Press, 2005.
5. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 (Suppl 3): S78-S89.
6. Naucler P, Ryd W, Tornberg S, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007; 97: 129-32.
7. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010; 340: c1804.
8. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
9. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
10. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
11. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
13. Hakama M, Auvinen A, Day NE, et al. Sensitivity in cancer screening. J Med Screen 2007; 14: 174-7.
14. Kotaniemi-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005; 93: 862-7.
15. Hristova L, Hakama M,. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997; 36 (Suppl 9): 1-60.
16. Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005; 14: 677-86.
17. Pukkala E, Malila N, Hakama M,. Socioeconomic differences in incidence of cervical cancer in Finland by cell type. Acta Oncol 2010; 49: 180-4.
18. Nieminen P, Kallio M, Hakama M,. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995; 85: 1017-21.
19. Jakobsson M, Gissler M, Paavonen J, et al. Loop electrosurgical excision procedure and the risk for preterm birth. Obstet Gynecol 2009; 114: 504-10.
20. Jakobsson M, Gissler M, Sainio S, et al. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2007; 109 (2 Part 1): 309-13.
21. Teppo L, Pukkala E, Lehtonen M,. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-9.
22. Lonnberg S, Leinonen M, Malila N, et al. Validation of histological diagnoses in a national cervical screening register. Acta Oncol 2012; 51: 37-44.
23. Fahey MT, Irwig L, Macaskill P,. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141: 680-9.
24. Sasieni P, Adams J, Cuzick J,. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89: 88-93.
25. Hakama M, Miller AB, Day N, eds. Screening for cancer of the uterine cervix (IARC Scientific Publications No. 76). Lyon: International Agency for Research on Cancer, 1986.
26. Sasieni P, Cuzick J,. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002;9:49-51.
27. Kotaniemi-Talonen L, Malila N, Nieminen P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008; 123: 2902-6.
28. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs. conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 1612-23.
29. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-6.
30. Nieminen P, Kallio M, Anttila A, et al. Organised vs. spontaneous Pap-smear screening for cervical cancer: A case-control study. Int J Cancer 1999; 83: 55-8.
31. Sankaranarayanan R, Chatterji R, Shastri SS, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer 2004; 112: 341-7.
32. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406.
33. Sankaranarayanan R, Nene BM, Dinshaw KA, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005; 116: 617-23.
34. Rebolj M, Lynge E,. Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen 2011; 17: 1-2.